A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.

Naveen K MehtaMartin PflueglerKristan MeetzeBochong LiIsabelle SindelFabian VogtMelanie MarklinJonas S HeitmannJoseph KauerLukas OsburgLatifa ZekriHans-Jörg BühringStefanie MuellerSebastian HörnerPatrick A BaeuerleJennifer S MichaelsonGundram JungHelmut R Salih

Published in: Journal for immunotherapy of cancer (2022)

CLN-049 has a favorable efficacy and safety profile in preclinical models, warranting evaluation of its antileukemic activity in the clinic.

Keyphrases

acute myeloid leukemia
primary care
tyrosine kinase
allogeneic hematopoietic stem cell transplantation
stem cells
combination therapy
mesenchymal stem cells